MaxCyte Inc. Secures Strategic Licensing Agreement with Adicet Bio

In a significant development for MaxCyte, Inc. (NASDAQ: MXCT), the biotechnology firm based in Gaithersburg, Maryland, has announced a strategic platform license agreement with Adicet Bio. This partnership, announced on August 4, 2025, underscores MaxCyte’s growing influence in the biotechnology sector, particularly in the realm of advanced cellular therapies.

MaxCyte, known for its comprehensive laboratory testing and research services, including protein production and cell analysis, has entered into a non-exclusive licensing agreement with Adicet Bio. This agreement grants Adicet Bio the rights to utilize MaxCyte’s innovative Flow Electroporation® technology and ExPERT™ platform. These technologies are pivotal in enhancing Adicet Bio’s proprietary manufacturing processes for allogeneic gamma delta T cell therapies, which are designed to combat cancer and autoimmune diseases.

The collaboration is poised to be mutually beneficial. MaxCyte will receive platform licensing fees and program-related revenue, providing a potential boost to its financial standing. As of August 4, 2025, MaxCyte’s stock closed at $2.06, with a market capitalization of approximately $219.22 million. Despite a challenging year, with a 52-week low of $1.965 recorded on July 31, 2025, this agreement could signal a positive shift for the company.

MaxCyte’s ExPERT™ platform is renowned for its high transfection efficiency, cell viability, and scalability, making it an ideal choice for Adicet Bio’s gene-edited programs. This partnership not only highlights MaxCyte’s technological prowess but also its strategic positioning within the biotechnology industry.

As the healthcare sector continues to evolve, MaxCyte’s collaboration with Adicet Bio represents a forward-looking approach to leveraging cutting-edge technology in the fight against some of the most challenging diseases. Investors and industry observers will be keenly watching how this partnership unfolds and its impact on MaxCyte’s future growth trajectory.